Fresh from the biotech pipeline: fewer approvals, but biologics gain share

Fresh from the biotech pipeline: fewer approvals, but biologics gain share

2022 saw a 25% drop in new drug approvals and a less predictable regulator.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature biotechnology 2023-02, Vol.41 (2), p.174-182
1. Verfasser: Senior, Melanie
Format: Artikel
Sprache:eng
Schlagworte:
Agriculture
Bioinformatics
Biological Factors
Biological Products - therapeutic use
Biomedical and Life Sciences
Biomedical Engineering/Biotechnology
Biomedicine
Biotechnology
Drug Approval
Life Sciences
News Feature
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:2022 saw a 25% drop in new drug approvals and a less predictable regulator.
ISSN:1087-0156
1546-1696
DOI:10.1038/s41587-022-01630-6